Related Experiment Video

Updated: Aug 17, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Possible involvement of the BDNF-dependent pathway in treatment-emergent suicidality or decreased response to

Shih-Jen Tsai1

  • 1Department of Psychiatry, Taipei Veterans General Hospital, No. 201 Shih-Pai Road, Sec. 2, 11217 Taipei, Taiwan. sjtsai@vghtpe.gov.tw

Medical Hypotheses
|July 9, 2005
PubMed

Insights

Antidepressants may cause suicidal tendencies or treatment failure by affecting brain-derived neurotrophic factor (BDNF) levels. Understanding these BDNF pathway mechanisms is crucial for improving antidepressant efficacy and patient outcomes.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Antidepressants are primary treatments for major depression.
  • A significant number of patients show poor response or develop suicidal tendencies.
  • The underlying mechanisms for these adverse effects remain unclear.

Purpose of the Study:

  • To propose mechanisms linking the brain-derived neurotrophic factor (BDNF) pathway to antidepressant treatment failure and suicidality.
  • To explore the role of BDNF and its receptor TrkB in antidepressant response.

Main Methods:

  • Review of existing animal and postmortem studies on antidepressant effects on BDNF and TrkB.
  • Hypothesizing potential dysregulations within the BDNF-TrkB pathway.

Main Results:

  • Several hypotheses are proposed: acute reduction in BDNF, dose-dependent effects, age-related changes in BDNF, altered TrkB receptor expression, TrkB pathway dysfunction, and antidepressant-induced mania.
  • These proposed mechanisms involve the brain-derived neurotrophic factor (BDNF) and its receptor tyrosine kinase B (TrkB) pathway.

Conclusions:

  • The BDNF-TrkB pathway is implicated in both therapeutic and adverse effects of antidepressants.
  • Further research into these proposed mechanisms could lead to personalized treatment strategies for non-responsive patients.

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
G-protein Coupled Receptors01:21

G-protein Coupled Receptors

G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Long-term Depression01:05

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Long-term Depression01:03

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over time, all...